Abscopal Effect from the Addition of Low-dose Radiotherapy in Metastatic Cancer Patients Receiving Stereotactic Body Radiotherapy: a Multicenter, Randomized Clinical Study

Stereotactic body radiotherapy (SBRT) has been known to enhance the abscopal effect by up to 40% when delivered with immune checkpoint inhibitors (ICIs). Recently, preclinical and clinical studies demonstrate that metastatic lesions treated with non-cytotoxic low-dose radiotherapy (LDRT) significantly were reduced in the condition where SBRT and ICIs were administered together. Given that ICIs are highly expensive and some tumors are beyond the indications of ICIs, novel approaches are required to boost the abscopal effect in the absence of ICIs. Therefore, the investigators design a multicenter, randomized clinical trial that investigates the efficacy and safety of LDRT combined with SBRT in metastatic cancer patients. The primary endpoint is a lesion-specific response of LDRT lesions (i.e., abscopal effect) evaluated three months after radiotherapy.
Subjects will be randomly allocated into two groups (1:1) with the stratification by planning target volume and previous use of ICIs: control group (SBRT in three fractions) or experimental group (SBRT + LDRT in three factions). Unless patients agree with randomization, subjects will participate in a prospective cohort study.

Start Date01 Jun 2025

Sponsor / Collaborator

Soonchunhyang University Hospital

[+1]

NCT06709170

/ Not yet recruitingNot ApplicableIIT

Safety & Efficacy of a Novel Asymmetrical Linear Stapler (NALS) for Securing Distal Resection Margin in Laparoscopic Rectal Cancer Surgery: Pilot Study

Through the use of a novel asymmetrical linear stapler (NALS, Meditulip co. Ltd.), we aim to prove that true distal margins greater than 1cm may be harvested more readily and easily compared to the conventional staplers. The study is designed as a pilot RCT of 30 patients in each group, with the primary outcome of distal margin length >1cm. Secondary outcomes include anastomosis dehiscence and time taken to harvest the distal margin.

Start Date01 Mar 2025

Sponsor / Collaborator

Seoul National University Hospital

[+4]

NCT06730893

/ Not yet recruitingNot ApplicableIIT

Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer: a Multicenter Randomized Controlled Trial

The objective of this study is to determine whether the use of shared decision support tools and protocols for treatment decisions in low-risk thyroid cancer patients has improved satisfaction with the decision-makings.

Start Date01 Feb 2025

Sponsor / Collaborator

National Cancer Center Korea

[+4]

100 Clinical Results associated with SMG-SNU Boramae Medical Center

0 Patents (Medical) associated with SMG-SNU Boramae Medical Center

1,153

Literatures (Medical) associated with SMG-SNU Boramae Medical Center

01 Feb 2025·Journal of Aging and Physical Activity

Lumbar Extensor Muscle Strength and Physical Performance in Community-Dwelling Older Adults: Findings From SarcoSpine Cohort

Article

Author: Kim, Dong Hyun ; Lee, Sang Yoon ; Kim, Seungcheol ; Oh, Sohee

Background: The lumbar extensor muscles (LEMs) play an important role in body posture and physical function in older adults. Because lumbar extensor strength decreases more rapidly than limb muscle strength with age, it should be evaluated to aid healthy aging. This study investigated the association between LEM strength and physical performance in community-dwelling older adults. Methods: This prospective observational cohort study of spinal sarcopenia (SarcoSpine) was conducted at a single center. One hundred and ten consecutive individuals who completed the baseline survey, including conventional sarcopenic indices, lumbar spine three-dimensional magnetic resonance imaging, isokinetic lumbar extensor strength, and physical performance tests (Short Physical Performance Battery, Berg Balance Scale, and Back Performance Scale [BPS]), were enrolled. A multivariate linear regression analysis was performed to determine the variables for evaluating their association with LEM strength. Results: Among the conventional sarcopenic indices, gait speed was significantly correlated with Short Physical Performance Battery results and Berg Balance Scale score in men and women. Handgrip strength was significantly correlated with the BPS score for both sexes. In the multivariable linear regression, age (β = −2.12, p < .01) and BPS score (β = −3.54, p = .01, R2 = .29) were independent indicators of LEM strength. Conclusions: Our findings reveal the substantial association between LEM strength and BPS score in older women. The targeted intervention aimed at improving the LEMs strength would be needed to enhance physical performance in the aging population.

01 Feb 2025·Annals of Surgery

Clinical Efficacy of Laparoscopic Sentinel Node Navigation Surgery for Stomach Preservation in Patients With Early Gastric Cancer

Article

Author: Nam, Byung-Ho ; Jeong, Sang-Ho ; Lee, Young Joon ; Yeong An, Ji ; Eom, Bang Wool ; Kook, Myeong-Cherl ; Jung, Mi Ran ; Park, Ji-Ho ; Hyung, Woo Jin ; Min, Jae-Seok ; Park, Young-Kyu ; Ryu, Keun Won ; Yoon, Hong Man ; Kim, Young-Woo ; Seok Cho, Gyu ; Hur, Hoon ; Han, Mira

Objective:This study aimed to compare laparoscopic standard gastrectomy (LSG) and laparoscopic sentinel node navigation surgery (LSNNS) for early gastric cancer (EGC) in terms of 5-year long-term oncologic outcomes.Background:The oncological safety of LSNNS for EGC has not been confirmed. Three-year disease-free survival (DFS), which is the primary endpoint of phase III multicenter randomized controlled clinical trial [SEntinel Node ORIented Tailored Approach (SENORITA) trial], did not show the noninferiority of LSNNS relative to LSG.Methods:The SENORITA trial, a multicenter randomized clinical trial, was designed to show that LSNNS is noninferior to LSG in terms of 3-year DFS. In the present study, we collected 5-year follow-up data from 527 patients recruited in the SENORITA trial as the full analysis set. DFS, overall survival (OS), disease-specific survival (DSS), and recurrence patterns were evaluated using the full analysis set of both LSG (n=269) and LSNNS (n=258).Results:The 5-year DFS was not significantly different between the LSG and LSNNS groups (P=0.0561). During the 5-year follow-up, gastric cancer–related events, such as metachronous cancer, were more frequent in the LSNNS group than in the LSG group. However, 10 recurrent cancers in the remnant stomach of both groups were curatively resected by additional gastrectomy and 1 by additional endoscopic resection. Two of the 198 patients who underwent local resection for stomach preservation based on the LSNNS results developed distant metastasis. However, there was no statistically significant difference in the 5-year OS and DSS (P=0.7403 and P=0.9586, respectively) between the two groups.Conclusions:The 5-year DFS, DSS, and OS did not differ significantly between the two groups. Considering the benefits of LSNNS on postoperative quality of life, LSNNS could be recommended as an alternative treatment option for EGC.

08 Jan 2025·Clinical Psychopharmacology and Neuroscience

Autonomic Readiness for Social Threats in Patients with Social Anxiety Disorder

Author: Kim, So-Yeon ; Lee, Dasom ; Kang, Deung Hyun ; Kim, Si Woo ; Lee, Joongsuk ; Choi, Soo-Hee ; Kim, Jae Hyun

News (Medical) associated with SMG-SNU Boramae Medical Center

12 Oct 2022

·www.healthcareitnews.com

5 South Korean hospitals to try out Deep Bio's AI support tool for prostate cancer diagnosis

South Korean medical AI developer Deep Bio is deploying its prostate cancer diagnosis support software to five local hospitals as part of a recently signed trial purchase agreement. The AI product will be tried out at SMG-SNU Boramae Medical Center, Chungnam National University Sejong Hospital, Korea Institute of Radiological & Medical Sciences, Jeju National University Hospital, and Gyeongsang National University Changwon Hospital. WHAT IT'S ABOUT The trial purchase comes ahead of the full integration of Deep Bio's DeepDx Prostate Pro into the hospitals' pathology workflows by November. It is intended to be used to support pathologists in tumour severity determination, confirmation of diagnoses, and research. The deep learning-based medical software analyses the whole slide image of prostate needle biopsies and automatically classifies the severity of prostate cancer. Based on evaluation studies, this tool showed 98.7% concordance in grade group classification and 96.9% concordance in "no grade" group classification compared with the reference standard created by three pathologists. THE LARGER TREND In November last year, Deep Bio received the approval of the Ministry of Food and Drug Safety for DeepDx Prostate Pro. In July this year, the software has been designated as an innovative product by South Korean regulators. The technology is currently being studied by researchers at the Stanford University School of Medicine, which recently extended its software license deal with the company. DeepDx Prostate is also being used by Morphle Labs' pathologists in India and the US. It is also being distributed around Switzerland and North Africa through Deep Bio's partnership with Swiss medical device distributor HealthCare Konnect. ON THE RECORD In a press statement, CEO Sun-Woo Kim said that "through this trial purchase project, Deep Bio will lead the introduction of digital pathology in Korea as well as accelerate domestic market expansion." "We are greatly expecting to prove that our software can be seamlessly integrated into the current pathology workflows, bringing positive changes such as reducing pathologists' work burden and improving efficiency in real clinical settings," he added.

Collaborate

100 Deals associated with SMG-SNU Boramae Medical Center

100 Translational Medicine associated with SMG-SNU Boramae Medical Center

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 24 Jan 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

SMG-SNU Boramae Medical Center

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 24 Jan 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing